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Background: Little is known about the effects of intermittent hemodialysis on microcirculatory perfusion. The aim
of this study is to assess the effects of hemodialysis on microvascular perfusion using transcutaneous oxymetry
(TCPO2).
Methods: In this observational study, hourly TCPO2 measurements were performed during hemodialysis sessions.
Ankle brachial index (ABI) was carried out to classify patients according their vascular condition.
Results: 50 patients (mean age 70 ± 8 years old) were enrolled. Mean TCPO2 decreased significantly on average
23.9% between start and finish of hemodialysis. Severe ischemia (TCPO2 < 30 mmHg) and critical ischemia
(TCPO2 < 10 mmHg) occurred during dialysis in 47.1% and 15.5% respectively. Critical ischemia occurred only in
limbs with ABI < 0.9 (8.3%) or > 1.3 (28%). Patients with critical ischemia experienced a significantly larger decline in
mean blood pressure (32.4 ± 26.1 mmHg vs 12.7 ± 10.7 mmHg; P = 0.007) and a more pronounced ultrafiltration
(45.55 ± 16.9 ml/kg vs 35.17 ± 18.2 ml/kg; P = 0.04) compared to patients without ischemia. Clinical outcomes
(death or vascular procedures) were five times more frequent in patients who had developed critical ischemia
(55.7% vs 10.1% P = 0.01). The elevated age of patients, the low basal value of TCPO2, and the occurrence of critical
ischemia were more frequently associated with clinical outcome (P = 0.03, P = 0.048, P = 0.01 respectively).
Conclusions: This study demonstrates that hemodialysis induces microcirculatory injury, dependent on blood
pressure reduction, peripheral vascular state and ultrafiltration. The occurrence of critical ischemia is associated to
pejorative patient outcome and therefore, TCPO2 seems to be useful to avoid potential distal tissue damage during
hemodialysis.
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Peripheral arterial disease (PAD), traditionally defined by
an ankle brachial index (ABI) of ≤ 0.9 is highly prevalent
in dialysis patients and considered as a marker of poor
prognosis [1-4]. Patients with mediacalcosis (ABI > 1.3)
are also considered as presenting high vascular risk [4].
Short intermittent hemodialysis (HD) exerts significant
hemodynamic and metabolic effects. Conventional HD is
known to be associated with endothelial injury, elevated* Correspondence: ygal.benhamou@chu-rouen.fr
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distribution, and reproduction in any mediumlevels of oxidative stress and an inflammatory state leading
to accelerated atherosclerosis [5-7]. Patients undergoing
hemodialysis, have more frequent PAD procedures (lower
extremity amputations and bypasses), compared to the
general population, with poor prognosis [8]. Thus, early
diagnosis of PAD and subsequent optimized vascular per-
fusion in HD patients deserves special attention. Silent
limb microcirculatory injury is probably underestimated
and should be recognized to prevent the onset of macro-
vascular limbs complications. Therefore, improvement of
the hemodynamic tolerability of HD on microcirculatory
vessels is one way of reducing tissue damage. However,
despite improvements in HD techniques, unevaluatedtral Ltd. This is an open access article distributed under the terms of the
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mains high and could partially explain the high incidence
of vascular complications.
The use of transcutaneous oxymetry (TCPO2), a non
invasive vascular tool, allows monitoring of local arterial
blood flow and skin oxygenation [9,10]. TCPO2 is influ-
enced by both central arterial oxygen content and local fac-
tors, such as tissue perfusion. The positive role of TCPO2
in quantifying the degree of ischemia is well known in
the population at large [11]. Values of TCPO2 in a de-
cubitus position less than 30 mmHg or less than 10 mmHg
are considered as either severe or critical ischemia re-
spectively [11]. However, TCPO2 has been poorly studied
in hemodialysis and its performance in detecting severe is-
chemia in hemodialysis patients is not well known. Sato
et al. have shown that mean TCPO2 value was signifi-
cantly lower in HD patients without PAD than in control
subjects [12].
Our group has recently reported the usefulness of
TCPO2 in improving PAD diagnosis and assessing its se-
verity in hemodialysis populations. We have shown that
a TCPO2 lower than 40 mmHg at onset of hemodialysis
might identify patients either at high risk of death or re-
quiring vascular treatment [13].
However, only few data on the monitoring of cutane-
ous microcirculation using TCPO2 during hemodialysis
sessions are available. Santesson et al. investigated the ef-
fects of three consecutive hemodialysis sessions on periph-
eral microcirculation and macrocirculation and have shown
that TCPO2 decreased significantly during hemodialysis,
regardless of blood pressure reduction [14]. Unfortunately,
this latter study took into account, neither the hemodialysis
parameters (plasmatic volume reduction, total ultrafiltra-
tion) nor the peripheral vascular conditions of the pa-
tients. The aims of this study are firstly to clearly state the
hemodynamic effects of HD on microcirculatory perfusion
using TCPO2 as a monitoring tool and secondly to
recognize some parameters leading to pejorative outcomes
(cardiovascular death or vascular treatment requirement).
Methods
This observational study was approved by the Ethics
Committee of Rouen University Hospital, and all pa-
tients gave their informed consent prior to inclusion.
Patients
Patients were recruited from a single hemodialysis center,
between April and September 2010, and followed-up pro-
spectively for one year. The study population consisted of
patients with ESRD undergoing maintenance hemodialysis.
Inclusion criteria were: patients treated with maintenance
hemodialysis three times per week since at least 3 months
and a session length of 240 minutes. Patients with an
acute renal failure, or with a recent cardiovascular event(< 1 month) ie stroke, acute limb ischemia, acute coronary
syndrome were excluded. Of the 50 patients included for
analysis, 39 (78%) received dialysis with arterio-venous fis-
tulas, while the others patients had central venous cathe-
ters. The monitor of HD was Integra® (Hospal, Mirandola,
Italy) and only synthetic high-flux membranes were used.
The dialysate flow was 500 ml/mn (n = 42) or 750 ml/mn
(n = 8) while the blood flow ranged from 300 ml/mn
(n = 13) to 450 ml/mn. Relative blood volume (RBV) was
calculated during the session, expressed as a percentage of
initial blood volume, measured continusly by Hemoscan®
optical densitometer (Hospal, Mirandola, Italy).
Prior diagnosis of PAD was established based on ultra-
sonographic or angiographic results or, previous vascular
surgical or endovascular revascularizations.
Methods
Transcutaneous oxymetry (TCPO2)
All baseline TCPO2 measurements were performed at
the beginning of the HD session (T0) after measurement
of oxygen parameters by pulse oximetry monitoring.
Hourly TCPO2 measurements were taken on both limbs
until the end of the session (T240). TCPO2 was mea-
sured at the dorsum of both feet in the first intermeta-
tarsal space with the patient n supine position, in an
air-conditioned room maintained at 22°C. A double-
sided adhesive ring and contact liquid supplied by the
manufacturer was used to obtain a hermetic area for meas-
urement. TCPO2 was measured as above [9,15] by an elec-
trochemical transducer (TCMtm3, Radiometer GMBH,
Copenhagen, Denmark). The transducer was heated to
44°C to increase the permeability of the skin to oxygen
molecules at the measuring site. Calibration period was,
on average, 10 minutes and the TCPO2 signal was con-
tinuously recorded on computer software during 10 mi-
nutes. A value lower than 40 mmHg is considered to be
pathologic. Severe ischemia and critical limb ischemia
were retained when TCPO2 measurements were lower
than 30 and 10 mmHg respectively [4,16]. We calculated
the variation of TCPO2 corresponding to the variation of
TCPO2 between start and finish of hemodialysis.
Ankle brachial index (ABI) measurement
ABI was calculated as the ratio between the higher value
of systolic blood pressures at the anterior or posterior
tibial artery for each leg and, the brachial systolic pres-
sure recorded. Brachial systolic pressure was measured
at the shunt (vascular access) free arm. Systolic pressure
was detected with a hand-held 8 –MHz Doppler probe
while the patient was supine after 5 minutes rest. Only
ABI values of 0.90 or less were considered as abnormal
or pathologic and indicators for PAD diagnosis [16]. ABI
values of 1.3 or greater or incompressible arteries at
ankle level were considered to indicate mediacalcosis









Cardio Vascular History of Patients




Intermittent claudication 12 24
Rest pain 3 6
Ischemic cardiopathy 18 36
Dialysis vintage (years)
> 10 years 07 14
5 years < dialysis < 10 years 11 22
< 5 years 32 64
Vascular statue of Limbs
Peripheral arterial disease (ABI < 0.9) 15 15
Normal vascular state ( 0.9 < ABI < 1.3) 34 34
Mediacalcosis (ABI > 1.3) 50 51
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mal. ABI was determined by the same operator during
the entire study.
Follow-up
Follow-up visits were scheduled at 12 months from study
inclusion. During follow-up, patients were asked about
the necessity of a vascular treatment (revascularization or
amputation). Death from any cause was noted. A com-
bined end point (pejorative outcome) was then defined in-
cluding death and vascular procedures requirement.
Statistical analysis
Demographic data and clinical features were analysed
using descriptive methods. Quantitative variables were
expressed as mean +/− standard deviation and compared
using the Student-t-test, or Mann–Whitney U test as
appropriate. Comparison between groups was performed
using Chi-square test and in the 2*2 tables, Fisher’s
exact test as appropriate. The independence of each
limb was confirmed by intra-class correlation coefficient
measurement.
Statistical analyses were performed using STATVIEW
(Version 5.0 de SAS Institute Inc.) program. P value lower
than 0.05 was considered statistically significant.
Results
Baseline patient characteristics
The study included 50 patients from April to September
2010. We distinguished four groups of renal disease re-
sponsible for ESRD: diabetic nephropathy (16%), vascu-
lar nephropathy (22%), chronic glomerulonephritis (10%)
and others (52%) such as chronic interstitial nephritis,
polycystic kidney disease and nephrectomy.
Patients clinical features are listed in Table 1. The pa-
tient population was 27 males (54%) and 23 females
(46%). Mean age and body mass index were respectively
70 ± 8 years old and 26.9 +/− 6.6 kg/m2. Hypertension
(92%), diabetes (32%) and dyslipidemia (76%) were the
most prevalent comorbid chronic conditions. Approxi-
mately two thirds of patients were known to have at
least one cardiovascular injury (stroke, transient ische-
mic attack, myocardial infarction). Fifteen patients (30%)
suffered from PAD (intermittent claudication for 12 of
them and rest pain for 3 of them). Two patients had a
previous angioplasty of the superficial femoral artery and
one had been amputated.
ABI was analysed for each leg (one patient was ampu-
tated), the proportion of ABI lower than 0.9, greater
than 1.3 and normal was 15% (n = 15), 51% (n = 50) and
34% (n = 34) respectively.
Most patients (64%) had received dialysis less than
5 years prior to the study. Median length of dialysis is
3.2 years [0.7-29.5].Baseline TCPO2, evolution and variation of TCPO2
At the beginning of the dialysis session, mean oxygen satur-
ation value for all patients was 95 ± 6%, whereas mean base-
line TCPO2 for all limbs was 45.7 ± 15.5 mmHg (n = 99).
Eighty three of them had a TCPO2 greater than 30 mmHg
and 14 limbs had a TCPO2 lower than 30 mmHg without
critical ischemia. Among limbs with an ABI < 0.9 (n = 15)
or > 1.3 (n = 50), the mean baseline TCPO2 was reduced
compared to the normal ABI group (38 ± 16.9 mmHg;
46.5 ± 11.4 mmHg and 53.5 ± 15.5 mmHg respectively;
P = 0.0002 and P = 0.02).
In overall limbs, mean TCPO2 decreased significantly
during dialysis on average by 23.9% between T0 and T240
(45.7 ± 15.5 mmHg vs 33.5 ± 15.6 mmHg; P <0.0001)
(Figure 1). The absolute change of TCPO2 values was
similar between groups of limbs regarding their ABI meas-
urement (ABI < 0.9, ABI > 1.3 and normal ABI (Figure 2).
Severe ischemia (TCPO2 < 30 mmHg) and critical is-
chemia (TCPO2 < 10 mmHg) were always asymptomatic
and occurred during dialysis in 47.1% and 15.5% of limbs
respectively. Most of severe ischemia (87.5%) or critical
ischemia (93.3%) occurred at the third hour of dialysis
(Table 2).
Considering patients, at the beginning of HD session, 48
patients had TCPO2 > 10 mmHg in both limbs. During
Figure 1 Evolution of TcPO2 values at different times of measurement during haemodialysis. P < 0.05 was considered
statistically significant.
Benhamou et al. BMC Nephrology 2014, 15:4 Page 4 of 8
http://www.biomedcentral.com/1471-2369/15/4the HD session, critical ischemia and severe ischemia oc-
curred in 9 and 24 patients respectively. Only 15 patients
remained with a TCPO2 value greater than 30 mmHg.
Predictive factors of ischemia during hemodialysis
The onset of ischemia (severe or critical) was not related
to demographic characteristics such as age (67.8 ± 15.3 y
vs 75.3 ± 8.7 y; P = 0.13), hypertension (88.6 ± 5.5%, vs
100 ± 0%; P = 0.30) smoking (41.2 ± 8.6% vs 53.3 ± 13.3%;
P = 0.53) dyslipidemia (76.5 ± 7.4% vs 80 ± 10.7%; P =
0.82), diabetes (28.6 ± 7.7% vs 40 ± 13%; P = 0.51), strokeFigure 2 Evolution of TcPO2 values at different times of
measurements during hemodialysis according to ABI Group.history (25.7 ± 7.5% vs 13.3 ± 9.1%; P = 0.46), myocardial
infarction history (37.1 ± 8.3% vs 33.3% ± 12.6%; P = 0.79)
or the use of anti platelet agent (63.3 ± 3.6% vs 59.2 ±
5.3%; P = 0.84). Only the initial value of TCPO2 was as-
sociated with critical limb ischemia (34 ± 14.2 mmHg, vs
52 ± 12.2 mmHg; P < 0.01).
Peripheral vascular state
During HD, the incidence of severe ischemia was sta-
tistically higher in limbs with pathologic ABI (ABI <
0.9 or ABI > 1.3) than in the normal ABI group, (80%
vs 28.1% P = 0.0076) and (53.5% vs 28.1% P = 0.028).
Critical ischemia occurred only in the two pathologic
ABI groups (< 0.9, > 1.3, normal) in 8.3% and, 28% of
cases, respectively.
Among limbs with a normal ABI, none had experi-
enced a critical ischemia, and only 28% had a severe is-
chemia episode.
Arterial blood pressure (BP)
Systolic, diastolic and mean arterial pressure (MAP) trended
to decrease during dialysis and reached a significantTable 2 Evolution in the number of limbs according to
their ischemic status during the hemodialysis session
Start of HD T60 T120 T180 End of HD
Critical ischemia 2 8 11 12 6
Severe Ischemia 14 22 24 26 35
No ischemia 83 69 64 61 58
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the end of dialysis, all parameters were similar to those at
baseline. No difference was observed in blood pressure
variation between the 3 ABI groups. Critical ischemia is
related to a significantly larger decline in BP parameters:
The critical ischemia group patient experienced a signifi-
cantly larger decline in MAP (32.4 ± 26.1 mmHg vs 12.7 ±
10.7 mmHg; P = 0.007), in systolic BP (53.4 ± 50.7 mmHg
vs 23.5 ± 20.9 mmHg; P = 0.005) and in diastolic BP (23.1 ±
14.9 mmHg vs 10.1 ± 8.7 mmHg; P = 0.001) than patients
without ischemia.
Dialysis parameters
The mean total ultrafiltration volume in our study was
2459 ± 1197 ml. Adjusted to weight, the mean total
UF/weight was 36.71 ± 18.05 ml/kg. A significant differ-
ence was observed in ultrafiltration variations between the
group of patients whose limbs developed critical ische-
mia (45.55 ± 16.9 ml/kg vs 35.17 ± 18.2 ml/kg; P = 0.04)
compared to the healthy group. This result was also
present in case of severe ischemia (41.14 ± 20.15 ml/kg
vs 31.28 ± 15.56 ml/kg; P = 0.03). A positive correlation
was found between the variation of TCPO2 and the
values of ultrafiltration/weight (rho 0.397; p = 0.001)
(Figure 3). At the same time, mean decrease in RBV
after 4 hours of dialysis was −7.4 ± 3.9%. However, this
decrease was greater during the first two hours of the
session (−5.4% ± 2.7%) compared to the last two hours
(−2.0% ± 2%). There was no difference between groups
regarding final RBV in cases of severe ischemia and
























Figure 3 Line graph shows the correlation between variations of TcPO
A positive relationship was observed (p < 0.001).One year follow up
Thirteen patients (26%) died during the first year of
follow-up; the main causes of death were infectious dis-
ease (n = 4) and cardiovascular complications (n = 5).
Death occurred respectively in two third of cases in pa-
tients with ischemia (critical or severe). Six patients expe-
rienced new peripheral vascular events (revascularization
and/or amputation). Five of them had an episode of crit-
ical ischemia during dialysis. When using combined cri-
teria, including death from cardiovascular disease and
vascular treatment, the frequency of pejorative outcome
was five times higher in patients who had undergone at
least one episode of critical ischemia during HD (55.7% vs
10.1% P = 0.01). In univariate analysis, age of patients,
basal value of TCPO2, onset of critical ischemia and an
ABI < 0.9 were more frequently observed in patients
with pejorative outcome (P = 0.03, P = 0.048, P = 0.01
and P = 0.09 respectively).
Discussion
This observational study investigated the effect of HD
on the microcirculatory perfusion evaluated by TCPO2
measurements. The major findings are a decrease in
TCPO2 during HD dependant on blood pressure reduc-
tion, ABI, level of ultrafiltration, as well as a high inci-
dence of subclinical severe and critical limb ischemia
during the session, which is independently correlated with
a significant increase in pejorative outcome for patients.
Optimal fluid balance to maintain hemodynamic stabil-
ity during hemodialysis procedure is essential to improve





2 and the value of the ultrafiltration/Weight in patients.
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on macrocirculation stability regarding systemic blood
pressure and paying no attention to peripheral perfu-
sion. Although ABI seems to be sufficient to predict poor
outcome in haemodialysis patients, as confirmed by sev-
eral previous studies. Nevertheless TCPO2, which is a
real-time indicator of the perfusion of microcirculation
can be a useful additional tool to alert the physician when
distal injuries occur.
Mistrik et al. have recently demonstrated microcircula-
tory changes during HD by using laser Doppler methods
[18]. Previously, Weiss et al. published results on the de-
crease in the TCPO2 measurement during hemodialysis
and up to four hours after the end of the session [19].
Their results have been since confirmed in small cohorts
without exact data on the influence of hemodialysis pa-
rameters on TCPO2 recording [14]. Our results are con-
sistent with previous data but we have also investigated
both the patient’s clinical parameters as well as some
hemodialysis parameters to understand the mechanisms of
microcirculatory injury. Peripheral vascular hemodynamic
status is a condition which leads to the development of se-
vere and critical ischemia during hemodialysis. While pre-
vious studies have failed to show a statistical impact on
peripheral vascular status in the decrease in TCPO2, in this
study we found, that the pathological vascular profile of
limbs (PAD or mediacalcosis) revealed a major frequency
of ischemia compared to the normal ABI group. Patho-
logical limbs on the other hand had lower basal TCPO2
values and the same variation of arterial blood pressure
compared to normal limbs. Adaptive autoregulation of dis-
tal flow seemed to be impaired when total volemia de-
creased. The increase in peripheral vascular resistance to
maintain constant systemic arterial pressure lead to a drop
in microcirculatory perfusion. Thus in patients with altered
peripheral perfusion, hemodialysis would seem to be more
deleterious.
A decrease in arterial blood pressure is one factor
which is responsible for impairment in microcirculatory
outflow. All patients experienced a significant decrease
in arterial blood pressure during the hemodialysis ses-
sion before recovering their basal values at the end of the
session. The link between arterial systemic pressure and
TCPO2 is well established. Megerman et al. have shown
that TCPO2 decreased significantly and correlated posi-
tively with induced patient hypotension [20]. In the same
way, tissue oxygen tension, measured at a variety of sites
in both human and laboratory studies, appears to be a
sensitive indicator of organ perfusion in different shock
states [21,22]. Since intradialytic hypotension occurs in
25-55% of dialysis sessions [23], the concomitant decrease
in TCPO2 in our study is not surprising [24-26]. However,
in our study, the relative increase in TcPO2 and in MAP
during the last hour of the session could be explained byeffective vascular refilling of extra cellular volume. This
adaptive mechanism may be connected to the profile of
the variation of RBV as described by Santoro et al. [27].
Our results demonstrate a change in RBV in two phases,
resulting in the occurrence of refilling during the second
part of the session.
The other main parameter incriminated in distal
microcirculatory injury is total ultrafiltration volume
which is a predictive factor for the decrease in TCPO2
in our study. As the ratio between ultrafiltration and
weight is considered as a better indicator of the intensity
of volume loss, we choose to express our result using
this ratio. However, results were similar when the total
ultrafiltration was used (data not shown). It has been
shown previously that microvascular perfusion is re-
duced by ultrafiltration and can be restored temporarily
using the Trendelenburg position by increasing venous
return or by administration of a small volume to replace
the intravascular volume [28]. This adaptive procedure
leads to an ischemia reperfusion phenomenon which is
well known to aggravate tissue damage by producing re-
active oxygen species (ROS) and inflammatory cytokines
[29]. Stress and chronic inflammation are still the lead-
ing causes of atherosclerosis and cardiovascular mortal-
ity [30,31]. In our study, 45% of patients with normal
basal distal perfusion experienced inadequate limb blood
flow during HD subsequently developing microcircula-
tory injury leading to accelerated PAD. This result could
explain that pejorative outcomes are five times higher in
patients who had experienced limb ischemia episode
during HD compared to other patients. Likewise, this
phenomenon could explain in part why the rate of PAD
procedures in HD patients compared to other chronic
kidney disease patients is so high [32].
The major limitation of this study is the exclusion of pa-
tients with a recent cardiovascular event. It would have
been interesting to analyse the results in those patients in
whom peripheral vascular disease might be more preva-
lent. However, our cohort of patients already has a very
high prevalence of cardiovascular comorbidities because of
our recruitment in a tertiary center. Moreover, since our
population is small, we decided to assess hemodynamic ef-
fects on the most stable population as possible to not over
estimated the onset of vascular injuries and of pejorative
outcomes. In addition, our cohort of patients already has a
very high prevalence of cardiovascular comorbidities be-
cause of our recruitment in a tertiary center all patients re-
ceived the same HD technique and it is impossible to
generalize our results to others HD methods. Therefore,
further studies are required to compare the impact of the
different types of HD on microcirculatory perfusion. Add-
itionally, since previous studies have shown that changes in
TCPO2 may depend on type of dialyzer membranes
[12,33] the exclusive use of high-flux synthetic membranes
Benhamou et al. BMC Nephrology 2014, 15:4 Page 7 of 8
http://www.biomedcentral.com/1471-2369/15/4in our study may limit the generalization of our re-
sults. However, the trend is for maximum use of synthetic
high flow membranes to reduce bio incompatibility and
systemic consequences.
Conclusion
In conclusion, our findings demonstrate that HD is re-
sponsible for microcirculatory injuries which are most
important in patients with PAD. Better knowledge of the
vascular status of the patient would seem to be neces-
sary for patients undergoing HD. According to our re-
sults and previous reports, we believe that during HD,
TCPO2 is useful for monitoring variations in distal perfu-
sion and could assess tolerability against vascular damage.
Therefore, changes in of session duration, in type of mem-
branes used or in level of ultrafiltration could improve HD
tolerance and probably overall patient prognosis.
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